CLINICAL CASE OF DUCHENNE MYODYSTROPHY
https://doi.org/10.57256/2949-0715-2023-2-45-52
Abstract
The paper describes a clinical case of Duchenne myodystrophy at the stage of manifestation of clinical manifestations. The problems of diagnosing mutations in the DMD gene are considered. The paper presents clinical and laboratory data for Duchenne myodystrophy. It is noted that the difficulty of clinical diagnosis of Duchenne myodystrophy is associated with the presence of a preclinical period, in which the main diagnostic marker is an increase in transaminases, lactate dehydrogenase and creatine phosphokinase, as well as varying degrees of severity of clinical manifestations. Low alertness of doctors to hereditary pathology at the preclinical stage of the disease was noted. Molecular genetic diagnosis is difficult due to the large size of the DMD gene, which, when the reading frame is violated, gives a large number of different mutation variants. It is noted that modern pathogenetic therapy of this disease is ineffective, and the most promising areas of etiological treatment are gene therapy and cell technologies. Conclusion. Difficulties in diagnosing hereditary myodystrophy are associated with low awareness and alertness of doctors regarding hereditary pathology. For the effective treatment of patients with Duchenne myodystrophy, it is necessary to introduce etiological methods of treatment into medical activities.
About the Authors
Elena Anatolyevna TkachukRussian Federation
Darya Mikhailovna Barykova
Russian Federation
Igor Zhanovich Seminsky
Russian Federation
Tatyana Alexandrovna Astakhova
Russian Federation
Alena Borisovna Ilyina
Russian Federation
Nadezhda Nikolaevna Van
Russian Federation
Tatyana Borisovna Kostik
Russian Federation
Alexander Vadimovich Alekseev
Russian Federation
Mikhail Badmaevich Mangataev
Russian Federation
References
1. Царькова С.А., Ушакова Р.А., Громада Н.Е. и др. Прогрессирующая мышечная дистрофия Дюшенна – Беккера. Трудности диагностики. Доктор.Ру. 2020;19(10):61–65 [Tsarkova S.A., Ushakova R.A., Gromada N.E. et al. Progressive Duchenne – Becker Muscular Dystrophy. Challenges with Diagnosis. Doctor.Ru. 2020;19(10):61–65. (in Russian)]. DOI: 10.31550/1727-2378-2020-19-10-61-65
2. Деев Р.В., Мавликеев М.О., Бозо И.Я. и др. Генно-клеточная терапия наследственных заболеваний мышечной системы: современное состояние вопроса. Научно-практический журнал. Гены и клетки. 2014; IX(4):6–33. [Deev R.V., Mavlikeev M.O., Bozo I.Ya. et al. Gen-cell therapy of hereditary diseases of the muscular system: current status of the issue. Scientific and Practical Journal. Genes and Cells. 2014;IX(4):6– 33. (in Russian)].
3. Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol. 2014;33(1):1-12.
4. Muscular dystrophy, Duchenne type; DMD (# 310200). https://www.omim.org/entry/310200 [accessed: 05.05.2023].
5. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82(2):291-329. DOI:10.1152/physrev.00028.2001.
6. Duchenne and Becker muscular dystrophy. https://medlineplus.gov/genetics/condition/duchenne-and-becker-muscular-dystrophy/#causes [accessed: 05.05.2023].
7. Rutkove SB, Kapur K, Zaidman CM, et al. Electrical impedance myography for assessment of Duchenne muscular dystrophy. Ann Neurol. 2017;81(5):622-632. DOI:10.1002/ana.24874.
8. Fayssoil A, Abasse S, Silverston K. Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2017;4(1):17-23. DOI:10.3233/JND-160194.
9. Mercuri E, Muntoni F, Osorio AN, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res. 2020;9(5):341-360. DOI:10.2217/cer-2019-0171.
10. Boland BJ, Silbert PL, Groover RV, Wollan PC, Silverstein MD. Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediatr Neurol. 1996;14(1):7-12. DOI:10.1016/0887-8994(95)00251-0
11. Jones GE, Witkowski JA. Membrane abnormalities in Duchenne muscular dystrophy. J Neurol Sci. 1983;58(2):159-174. DOI:10.1016/0022-510x(83)90214-9.
12. Richards CS, Watkins SC, Hoffman EP, et al. Skewed X inactivation in a female MZ twin results in Duchenne muscular dystrophy. Am J Hum Genet. 1990;46(4):672-681.
13. Therapeutic Strategies. URL: https://www.jain-foundation.org/research/dysferlin-background/therapeutic-opportunities[accessed: 05.05.2023].
14. Miller JB, Girgenrath M. The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy. Trends Mol Med. 2006;12(6):279-286. DOI:10.1016/j.molmed.2006.04.003.
15. Bönnemann CG. The collagen VI-related myopathies: muscle meets its matrix. Nat Rev Neurol. 2011;7(7):379-390. DOI:10.1038/nrneurol.2011.81
16. Ткачук Е.А., Семинский И.Ж. Методы современной генетики. Байкальский медицинский журнал. 2023;2(1):60-71 [Tkachuk E.A., Seminsky I.Z. Methods of modern genetics. Baikal Medical Journal. 2023;2(1):60-71 (In Russian)]. DOI:10.57256/2949-0715-2023-1-60-71
Review
For citations:
Tkachuk E.A., Barykova D.M., Seminsky I.Zh., Astakhova T.A., Ilyina A.B., Van N.N., Kostik T.B., Alekseev A.V., Mangataev M.B. CLINICAL CASE OF DUCHENNE MYODYSTROPHY. Baikal Medical Journal. 2023;2(2):45-52. (In Russ.) https://doi.org/10.57256/2949-0715-2023-2-45-52